Our findings support previous biomarker studies in suggesting that plasma p-tau levels rise in response to early Aβ in preclinical AD3 but also add that this occurs mainly in the concomitant presence of astrocyte reactivity biomarker abnormality. Here, MAPT is linked to Alzheimer disease 3.